Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.85. Operator: Hello. Welcome to Vir ...

The panelist discusses how, expanding clinical trials, biomarker testing, and financial support improves access to emerging ...

(NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2024 and highlighted recent ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that, further to its engagement with Trusted Health ...